Meeting
2022 ASCO Annual Meeting
VOYAGER (KSCC1902): A single-arm, multicenter, phase II study of early induction of nivolumab during second-line treatment with taxane ± ramucirumab for advanced gastric or gastro-esophageal junction cancer.
Authors
Hiroo Katsuya
Division of Hematology, Respiratory Medicine and Oncology, Department of Internal Medicine, Faculty of Medicine, Saga University, Saga, Japan
Hiroo Katsuya , Akitaka Makiyama , Tomomi Kashiwada , Yudai Shinohara , Qingjiang Hu , Satoshi Otsu , Akira Yoneda , Yasunori Emi , Nobuya Ishibashi , Eto Kojiro , Masato Nakamura , Mototsugu Shimokawa , Eiji Oki , Hiroshi Saeki , Masaki Mori
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Esophageal or Gastric Cancer
Clinical Trial Registration Number
jRCTs071190025
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 4028)
DOI
10.1200/JCO.2022.40.16_suppl.4028
Abstract #
4028
Poster Bd #
16
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Final results from a phase II trial of CIMAvax-EGF and nivolumab as second-line (2L) therapy after platinum-based chemotherapy in advanced non-small cell lung cancer (NSCLC).
First Author: Rachel Frascati
First Author: Michael Masetti
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Bintrafusp alfa plus paclitaxel for advanced gastric cancer as a second-line treatment: An open label, single-arm, phase Ib/II study.
First Author: Choong-kun Lee
Poster
2022 ASCO Annual Meeting
The PRODIGE 59-DURIGAST trial: A randomized phase II study evaluating FOLFIRI plus durvalumab and FOLFIRI plus durvalumab plus tremelimumab in second-line treatment of patients with advanced gastric or gastro-esophageal junction adenocarcinoma.
First Author: David Tougeron